XRTX ▲ +21.9% - XORTX Therapeutics Inc. $XRTX - XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity XORTX Therapeutics shares rose 21.9% after the company announced plans to submit an Investigational New Drug application to the FDA for XRx-026, a treatment candidate within its gout program that uses the company's XORLO™ platform technology. The announcement targets a U.S. gout market opportunity valued at over $700 million, suggesting potential commercial scale for the program. 18-SEP-2026 08:05 AM ET